Meijer O C, de Lange E C, Breimer D D, de Boer A G, Workel J O, de Kloet E R
Division of Medical Pharmacology of the Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands.
Endocrinology. 1998 Apr;139(4):1789-93. doi: 10.1210/endo.139.4.5917.
Mice with a genetic disruption of the multiple drug resistance (mdr1a) gene were used to examine the effect of the absence of its drug-transporting P-glycoprotein product from the blood-brain barrier on the distribution and cell nuclear uptake of [3H]-dexamethasone in the brain. [3H]-dexamethasone (4 microg/kg mouse) was administered s.c. to adrenalectomized mdr1a (-/-) and mdr1a (+/+) mice. One hour later, the mice were decapitated, and the radioactivity was measured in homogenates of cerebellum, blood, and liver following extraction of the radioactive steroid. The frontal brain was cut in sections for autoradiography. In the cerebellum of the mdr1a mutants, the amount of [3H]-dexamethasone relative to blood was about 5-fold higher than observed in the controls, whereas the ratio in blood vs. liver was not different. Using autoradiography, it was found that brain areas expressing the glucocorticoid receptor (GR) in high abundance, such as the hippocampal cell fields and the paraventricular nucleus (PVN), showed a 10-fold increase in cell nuclear uptake of radiolabeled steroid. The amount of retained steroid increased toward levels observed in the pituitary, which contains a similar density of GRs. The [3H]-dexamethasone concentration in pituitary was not affected by mdr1a gene disruption. The GR messenger RNA expression pattern in hippocampus was not different between the wild types and mdr1a mutants, which rules out altered receptor expression as a cause of the enhanced dexamethasone uptake. In conclusion, the present study demonstrates that the brain is resistant to penetration by dexamethasone because of mdr1a activity at the level of the blood-brain barrier. The data support the concept of a pituitary site of action of dexamethasone in blockade of stress-induced ACTH release. Dexamethasone poorly substitutes for depletion of the endogenous glucocorticoid from the brain and therefore, in this tissue, may cause a condition resembling that of adrenalectomy.
利用多药耐药(mdr1a)基因发生遗传破坏的小鼠,研究血脑屏障中缺乏其药物转运P-糖蛋白产物对[3H]-地塞米松在脑内分布及细胞核摄取的影响。对肾上腺切除的mdr1a(-/-)和mdr1a(+/+)小鼠皮下注射[3H]-地塞米松(4微克/千克小鼠)。1小时后,将小鼠断头,提取放射性类固醇后,测定小脑、血液和肝脏匀浆中的放射性。将额叶脑切成切片用于放射自显影。在mdr1a突变体的小脑中,相对于血液的[3H]-地塞米松量比对照组高约5倍,而血液与肝脏的比值无差异。通过放射自显影发现,高表达糖皮质激素受体(GR)的脑区,如海马细胞区和室旁核(PVN),放射性标记类固醇的细胞核摄取增加了10倍。保留的类固醇量增加至垂体中观察到的水平,垂体中GRs密度相似。垂体中的[3H]-地塞米松浓度不受mdr1a基因破坏的影响。野生型和mdr1a突变体海马中的GR信使RNA表达模式无差异,这排除了受体表达改变是地塞米松摄取增强的原因。总之,本研究表明,由于血脑屏障水平的mdr1a活性,脑对地塞米松的穿透具有抗性。数据支持地塞米松在阻断应激诱导的促肾上腺皮质激素释放中的垂体作用位点的概念。地塞米松不能很好地替代脑内内源性糖皮质激素的消耗,因此,在该组织中,可能导致类似于肾上腺切除的状态。